JP7771064B2 - 脾腫を治療する方法 - Google Patents

脾腫を治療する方法

Info

Publication number
JP7771064B2
JP7771064B2 JP2022542216A JP2022542216A JP7771064B2 JP 7771064 B2 JP7771064 B2 JP 7771064B2 JP 2022542216 A JP2022542216 A JP 2022542216A JP 2022542216 A JP2022542216 A JP 2022542216A JP 7771064 B2 JP7771064 B2 JP 7771064B2
Authority
JP
Japan
Prior art keywords
weeks
myelofibrosis
bid
human subject
btk inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022542216A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021142257A5 (https=
JP2023509968A (ja
JP2023509968A5 (https=
Inventor
ウェイン フィリップ ロスバウム，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telios Pharma Inc
Original Assignee
Telios Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telios Pharma Inc filed Critical Telios Pharma Inc
Publication of JP2023509968A publication Critical patent/JP2023509968A/ja
Publication of JPWO2021142257A5 publication Critical patent/JPWO2021142257A5/ja
Publication of JP2023509968A5 publication Critical patent/JP2023509968A5/ja
Priority to JP2025186533A priority Critical patent/JP2026027353A/ja
Application granted granted Critical
Publication of JP7771064B2 publication Critical patent/JP7771064B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Solid Wastes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
JP2022542216A 2020-01-08 2021-01-08 脾腫を治療する方法 Active JP7771064B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025186533A JP2026027353A (ja) 2020-01-08 2025-11-05 脾腫を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062958632P 2020-01-08 2020-01-08
US62/958,632 2020-01-08
PCT/US2021/012696 WO2021142257A1 (en) 2020-01-08 2021-01-08 Methods of treating splenomegaly

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025186533A Division JP2026027353A (ja) 2020-01-08 2025-11-05 脾腫を治療する方法

Publications (4)

Publication Number Publication Date
JP2023509968A JP2023509968A (ja) 2023-03-10
JPWO2021142257A5 JPWO2021142257A5 (https=) 2024-01-17
JP2023509968A5 JP2023509968A5 (https=) 2024-01-17
JP7771064B2 true JP7771064B2 (ja) 2025-11-17

Family

ID=76788747

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022542216A Active JP7771064B2 (ja) 2020-01-08 2021-01-08 脾腫を治療する方法
JP2025186533A Pending JP2026027353A (ja) 2020-01-08 2025-11-05 脾腫を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025186533A Pending JP2026027353A (ja) 2020-01-08 2025-11-05 脾腫を治療する方法

Country Status (15)

Country Link
EP (2) EP3980069A4 (https=)
JP (2) JP7771064B2 (https=)
KR (1) KR20220130151A (https=)
CN (1) CN114423457A (https=)
AU (1) AU2021205484A1 (https=)
BR (1) BR112022013646A2 (https=)
CA (1) CA3164063A1 (https=)
CO (1) CO2022010592A2 (https=)
CR (1) CR20220374A (https=)
IL (1) IL294582A (https=)
JO (1) JOP20220168A1 (https=)
MA (3) MA63848B1 (https=)
MX (1) MX2022008490A (https=)
TN (1) TN2022000185A1 (https=)
WO (1) WO2021142257A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3980069A4 (en) * 2020-01-08 2022-08-17 Telios Pharma, Inc. METHODS OF TREATMENT OF SPLENOMEGALY
US20240024314A1 (en) 2020-01-08 2024-01-25 Telios Pharma, Inc. Methods of Treating Splenomegaly
IL309238A (en) * 2021-06-16 2024-02-01 Telios Pharma Inc Treatment of symptoms associated with myeloproliferative tumors
WO2023071973A1 (en) * 2021-10-26 2023-05-04 Shenzhen Targetrx, Inc. Fused bicyclic compound for inhibiting activity of tyrosine kinase
CN119677518A (zh) * 2022-08-25 2025-03-21 百济神州(苏州)生物科技有限公司 包含(s)-7-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺和草酸的固体形式、其组合物及其使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016537433A (ja) 2013-11-26 2016-12-01 ギリアード サイエンシーズ， インコーポレイテッド 骨髄増殖性障害を処置するための治療
WO2019243223A1 (en) 2018-06-19 2019-12-26 Merck Patent Gmbh Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
MA40596B1 (fr) * 2014-08-11 2021-12-31 Acerta Pharma Bv Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
WO2016054491A1 (en) * 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN109942835A (zh) * 2019-03-27 2019-06-28 广州楹鼎生物科技有限公司 一种催化分解木质纤维原料的方法
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
EP3980069A4 (en) * 2020-01-08 2022-08-17 Telios Pharma, Inc. METHODS OF TREATMENT OF SPLENOMEGALY

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016537433A (ja) 2013-11-26 2016-12-01 ギリアード サイエンシーズ， インコーポレイテッド 骨髄増殖性障害を処置するための治療
WO2019243223A1 (en) 2018-06-19 2019-12-26 Merck Patent Gmbh Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Blood，2018年，Vol.132 (Supplement 1), 2623，<https://doi.org/10.1182/blood-2018-99-118802>

Also Published As

Publication number Publication date
EP4000624A1 (en) 2022-05-25
AU2021205484A1 (en) 2022-08-18
JP2026027353A (ja) 2026-02-18
MA57226B1 (fr) 2023-06-28
CR20220374A (es) 2023-01-25
MA57226A1 (fr) 2023-02-28
EP3980069A1 (en) 2022-04-13
JOP20220168A1 (ar) 2023-01-30
CO2022010592A2 (es) 2022-10-31
MX2022008490A (es) 2022-10-13
MA63848A1 (fr) 2024-04-30
JP2023509968A (ja) 2023-03-10
MA63848B1 (fr) 2024-10-31
TN2022000185A1 (en) 2024-04-01
MA69153A1 (fr) 2025-07-31
KR20220130151A (ko) 2022-09-26
CA3164063A1 (en) 2021-07-15
WO2021142257A1 (en) 2021-07-15
BR112022013646A2 (pt) 2022-10-04
IL294582A (en) 2022-09-01
EP3980069A4 (en) 2022-08-17
CN114423457A (zh) 2022-04-29

Similar Documents

Publication Publication Date Title
JP7771064B2 (ja) 脾腫を治療する方法
JP5046922B2 (ja) 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物
TW201840337A (zh) 使用ｈｓｐ９０抑制劑治療癌症的方法
TW200539869A (en) Antineoplastic combinations of CCI-779 and rituximab
JP2023502067A (ja) 癌治療のためのｂｔｋ阻害剤及びｍｄｍ２阻害剤の組合せ
JP2024050668A (ja) がんの治療方法
JP2024526092A (ja) 骨髄増殖性新生物と関連した症状の治療
TW201922256A (zh) 治療淋巴樣惡性疾病之方法
CN108367006A (zh) 用于治疗血液癌症的赛度替尼
US11642343B2 (en) Methods of treating splenomegaly
CN111629718A (zh) 对癌症患者的治疗有用的尿碱剂
CA2672716C (fr) Nouvelle utilisation therapeutique pour le traitement des leucemies
JP2025539944A (ja) 骨髄増殖性新生物を処置する方法
JP2008514721A (ja) 治療方法
HK40078282A (en) Btk inhibitors for treating splenomegaly
AU2023356925A1 (en) Improved treatment of cancers using combinations of SMARCA2 degraders and KRAS targeting therapies
CA3268732A1 (en) Improved treatment of cancers using combinations of smarca2 degraders and kras targeting therapies
HK40078526A (en) Methods and regimens for the treatment of hematological cancer
EA045240B1 (ru) Способы лечения рака

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250728

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251105

R150 Certificate of patent or registration of utility model

Ref document number: 7771064

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150